# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO® & FYLNETRA®)ADL018 is Kashiv's lead p...
https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker A...
Amneal's Q2 2024 injectable product launches: Product launchDosage formASHP drug shortage1PEMRYDI RTU®VialNo2Atropine sulfa...
Significantly expanding access to affordable, life-saving opioid overdose rescue medicineEntered distribution agreement with Ca...
Goldman Sachs analyst Nathan Rich maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from...
Truist Securities analyst Les Sulewski reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price targe...
Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 ear...